Stock Alert: Clearside Biomedical Continues To Trade Higher

Shares of biopharmaceutical company Clearside Biomedical, Inc. (CLSD) are trading up 28 percent on Thursday. The stock has been on an upward trajectory ever since it announced
positive safety results from an early-stage trial for the treatment of a chronic eye disorder earlier this week.

On Tuesday, the company announced positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered in six patients with neovascular age-related macular degeneration, which causes blurred vision or a blind spot in the patient's visual field.

Currently trading at $5.25, the stock has traded between $1.25 and $5.95 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT